Biotech Values

[DewDiligence]

PBMD +41%/AH on safety/biomarker data in breast cancer:

http://finance.yahoo.com/news/prima-biomed-announces-data-imp321-213339251.html

In this Phase IIb study of IMP321 plus paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer, data from all 15 patients in the safety run-in phase demonstrated that IMP321 is safe and well tolerated at both the 6mg and 30mg dosage levels.

Immune monitoring data has also confirmed that IMP321, as an Antigen Presenting Cell (APC) activator, is working to generate the desired immune responses. The data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells.

“…we look to commence the enlarged randomised and double-blind phase in the new year. We also look forward to providing further insights into efficacy of these safety run in patients by the middle of 2017."

So, there are not yet any randomized efficacy data.

IMP321 is a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3… MP321 has been shown in an open-label Phase I study to be able to double the expected six-month response rate in HER-2 negative metastatic breast cancer patients receiving standard-of-care paclitaxel; from a 25% historic response rate, to 50% when combined with IMP321.